AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

Core Insights - AIM ImmunoTech Inc. announced that data from its Phase 2 clinical study on cisplatin-resistant advanced recurrent ovarian cancer using Ampligen (rintatolimod) was accepted for presentation at the 40th Annual SITC Meeting [1] - The study focuses on a combination locoregional chemoimmunotherapy approach and its correlation with clinical outcomes [1] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company dedicated to developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [2] - The company's lead product, Ampligen (rintatolimod), is a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator [2]